PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Canakinumab - Hyperuricaemia and Gout

PAD Profile : Canakinumab - Hyperuricaemia and Gout

Brand Names Include :
Ilaris

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
NICE Technology Appraisal
NICE TA281 Canakinumab for Gout (Terminated Appraisal)

Committee Recommendations

Date
Committee Name
Narrative
29 May 2013
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks because no evidence submission was received from the manufacturer of the technology. Canakinumab not currently supported by the Prescribing Clinical Network

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.04. Gout and cytotoxic induced hyperuicaemia
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More